First Turn Management LLC Buys Shares of 1,892,683 Fulcrum Therapeutics, Inc. $FULC

First Turn Management LLC bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,892,683 shares of the company’s stock, valued at approximately $21,406,000. Fulcrum Therapeutics accounts for approximately 2.4% of First Turn Management LLC’s holdings, making the stock its 20th largest position. First Turn Management LLC owned approximately 3.50% of Fulcrum Therapeutics as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics during the 4th quarter valued at about $30,000. Quarry LP acquired a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $35,000. Meeder Asset Management Inc. acquired a new position in Fulcrum Therapeutics during the 4th quarter valued at about $39,000. Russell Investments Group Ltd. increased its stake in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the period. Finally, Assetmark Inc. acquired a new position in Fulcrum Therapeutics during the 3rd quarter valued at about $88,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, June 2nd. Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 price objective for the company. in a research report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. Finally, Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, Fulcrum Therapeutics presently has an average rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $3.45 on Friday. Fulcrum Therapeutics, Inc. has a one year low of $2.83 and a one year high of $15.74. The company has a 50-day moving average of $6.59 and a two-hundred day moving average of $8.82. The stock has a market cap of $229.87 million, a price-to-earnings ratio of -3.00 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. Analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.76 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.